Prestige BioPharma Limited
KSE:950210.KS
17360 (KRW) • At close July 2, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) KRW.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Revenue
| 689.075 | 161.841 | 0 | 0 | 0 | 2,089.006 | 0 |
| Cost of Revenue
| 1,217.868 | 11,658.824 | 3,869.223 | 1,667.164 | 123.869 | 755.331 | 240.237 |
| Gross Profit
| -64,977.393 | -11,496.857 | -3,869.223 | -1,667.164 | -1,185.412 | 1,333.675 | -240.237 |
| Gross Profit Ratio
| -94.297 | -71.038 | 0 | 0 | 0 | 0.638 | 0 |
| Reseach & Development Expenses
| 23,436.692 | 40,914.136 | 17,708.937 | 10,130.377 | 4,198.732 | 2,322.557 | 1,365.626 |
| General & Administrative Expenses
| 17,204.878 | 28,720.182 | 724.565 | 600.86 | 1,152.139 | 2,568.348 | 0 |
| Selling & Marketing Expenses
| 12,694.298 | 10,877.046 | 18,587.431 | 8,711.365 | 5,052.51 | 0 | 0 |
| SG&A
| 10,604.199 | -53,445.979 | 101,194.08 | 6,585.161 | 7,514.141 | 3,415.225 | 1,629.44 |
| Other Expenses
| 33,572.832 | 0 | 15,670.177 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 63,472.008 | 69,734.534 | 58,516.239 | 16,715.538 | 10,873.116 | 5,737.782 | 2,995.066 |
| Operating Income
| -62,782.933 | -69,572.693 | -118,823.179 | -18,384.005 | -10,873.118 | -4,404.107 | -3,235.304 |
| Operating Income Ratio
| -91.112 | -429.883 | 0 | 0 | 0 | -2.108 | 0 |
| Total Other Income Expenses Net
| 8,093.602 | 67,477.206 | -91,826.295 | 11,027.668 | -3,190.146 | 3,143.963 | 1,006.984 |
| Income Before Tax
| -54,689.331 | -2,095.487 | -210,649.475 | -7,356.859 | -14,898.393 | -1,260.144 | -2,228.32 |
| Income Before Tax Ratio
| -79.366 | -12.948 | 0 | 0 | 0 | -0.603 | 0 |
| Income Tax Expense
| 408.679 | 763.278 | 800.662 | 34.077 | 98.473 | 187.343 | 0 |
| Net Income
| -32,921.237 | 17,569.286 | -211,450.136 | -7,390.936 | -14,996.866 | -1,447.487 | -2,228.32 |
| Net Income Ratio
| -47.776 | 108.559 | 0 | 0 | 0 | -0.693 | 0 |
| EPS
| -547.81 | 292.35 | -3,518.53 | -135.99 | -49.91 | -4.82 | -7.42 |
| EPS Diluted
| -547.81 | 292.35 | -3,518.53 | -135.99 | -49.91 | -4.82 | -7.42 |
| EBITDA
| -31,047.549 | 10,513.246 | -206,905.073 | -5,682.976 | -13,718.872 | -686.466 | -1,987.833 |
| EBITDA Ratio
| -45.057 | 64.96 | 0 | 0 | 0 | -0.329 | 0 |